Aytu Biopharma (AYTU) Total Liabilities (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Total Liabilities data on file, last reported at $111.7 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 10.07% year-over-year to $111.7 million in Q1 2026; TTM through Mar 2026 was $111.7 million, a 10.07% decrease from a year earlier, with the FY2025 full-year figure at $124.2 million, up 5.15% from the prior year.
• Total Liabilities for Q1 2026 stood at $111.7 million, down from $122.0 million in the prior quarter.
• Over the last five years, Total Liabilities for AYTU reached as high as $131.2 million in Q4 2023 and fell as low as $93.3 million in Q2 2022.
• Historically, Total Liabilities has averaged $112.9 million across 5 years, with a median of $115.8 million in 2024.
• On a YoY basis, Total Liabilities climbed as much as 72169.8% in 2022 and fell as far as 27.15% in 2022.
• Year by year, Total Liabilities stood at $95.6 million in 2022, then soared by 37.26% to $131.2 million in 2023, then slipped by 11.45% to $116.2 million in 2024, then grew by 4.97% to $122.0 million in 2025, then slipped by 8.45% to $111.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $111.7 million in Q1 2026, $122.0 million in Q4 2025, and $125.0 million in Q3 2025.